Gapping up
In reaction to strong earnings/guidance:
- FAST +9%, SAP +8.5%, SAVE +2.9% (estimates Q3 TRASM and Adjusted CASM ex-fuel will be better than previously estimated), INFY +2.4%
Select financial related names showing strength:
- LYG +12.6%, DB +4.6%, HSBC +4.3%, SAN +3.3%, CS +3.2%, BBVA +2.6%
Select Chinese stocks trading higher:
- JD +2.6%, BABA +2.2%, BIDU +1.8%, WB +1.6%, ASHR +0.9%
Select oil/gas related names showing strength:
- TOT +2.5%, SLB +1.7%, HAL +1.4%, XOM +1.1%, RDS.A +0.9%, BP +0.8%, PSX +0.8%
Other news:
- APPN +4.3% (higher following SAP guidance)
- TLRY +2.7% (Tilray JV Fluent Beverage Company announces plans to commercialize non-alcohol CBD-infused beverages in Canada)
- WORK +2.4% (Slack reports that during Sept people actively using Slack every day exceeded 12 mln; has nearly 600,000 daily active registered developers)
- GILD +0.8% (Gilead Sciences and Galapagos [GLPG] announce efficacy and safety results of filgotinib through 52 weeks in FINCH 1 and FINCH 3 studies in Rheumatoid Arthritis were consistent)
- KIN +0.6% (announces positive CVMP opinion for Mirataz for cats experiencing poor appetite and weight loss)
Analyst comments:
- ROKU +7.2% (upgraded to Outperform from Sector Perform at RBC Capital Mkts )
- TTD +4% (upgraded to Outperform at RBC Capital Mkts)
- WDAY +3.5% (upgraded to Buy from Neutral at Goldman)
- PLAN +3.3% (initiated with a Buy at Mizuho)
- SNDR +2.7% (upgraded to Buy from Neutral at UBS)
- TWLO +2.7% (initiated with an Outperform at RBC Capital Mkts)
- FITB +2.6% (upgraded to Buy from Neutral at BofA/Merrill)
- SAM +2.3% (upgraded to Buy from Neutral at Citigroup)
- PRGO +2.3% (upgraded to Buy from Hold at Argus)
- PGRE +2% (upgraded to Overweight from Equal-Weight at Morgan Stanley),
- COUP +1.6% (initiated with a Neutral at Mizuho)
- SQ +1.4% (upgraded to Positive from Neutral at Susquehanna)
- JNJ +1.3% (upgraded to Outperform from Mkt Perform at Bernstein)